Pharma's complicated global supply chains will undoubtedly face a slew of new and unprecedented challenges brought on by the global COVID-19 outbreak. However, big pharma is confident they’ll be able to handle the strain without sacrificing integrity. To keep you up to date on the latest developments, DOWNLOAD this abbreviated overview of how 6 pharma companies are taking on the COVID-19 pandemic.

There are few things in life more frightening than a cancer diagnosis. With that in mind, ensuring that gene & cell therapy supply chains are as expedient and effective as possible. Considering the complex and time-sensitive nature of such supply chains, this can be incredibly challenging.

To get you started on your own Car-T logistics journey, we created this interactive presentation that walks you through the stages, challenges and opportunities associated with building a resilient and customer-centered Car-T supply chain.

First of all, let me emphasise that the impact of COVID-19 on pharma logistics is, and will continue to be, enormous. The ease of occurrence and the pace of progression associated with this particular pandemic crisis has stunned the entire logistics sector and shocked the world. Air freight, in particular, has been hugely disrupted, and the suddenness of the situation literally caught the industry with its pants down.

Be in no doubt, the massive cutbacks we are currently seeing in air transport capacity is extremely worrying news for pharma logisticians. While medicines continue to be delivered by air with some extraordinary efforts, the current temporary air cargo boost is unsustainable without the infrastructure and effective subsidies from PAX flying. Planes are being sold and mothballed at an unprecedented rate. And not only are airlines massively cutting back, all airports are closing at least some of their doors.

These doors, along with the supporting infrastructure, may never reopen. Singapore’s Changi Airport, for example has closed its huge Terminal 2 and I understand that they are now considering mothballing Terminal 4. This is a picture that is being repeated around the world with 75% of global flight capacity currently grounded.

 With this in mind, it goes without saying that the post-pandemic pharma transportation and distribution system will need to be much more robust, resilient and diverse in order to cope with reduced air freight capacity, higher freight costs and the possibility in the future of similar emergencies and disruptive events.

Therefore a lot of changes are going to be necessary if we are to make the supply chain more shock-proof and nimble after the crisis subsides...Fill Out Form Below to Read More

In conjunction with this year’s regional and global forums on time- and temperature-controlled logistics for life sciences, IQPC has conducted a survey involving pharma manufacturers, logistics and transportation providers and packaging developers. The key takeway: the old standby term “cold chain” no longer encompasses the range of services and technologies important to the industry. And despite the flow of new technologies that have been showcased by IQPC since its first global forum, 18 years ago, there is still a strong appetite for innovation and new technology: operational managers believe that a better supply chain for time- and temperature-controlled products is possible.

DOWNLOAD our latest industry report to find out: 

• How the "cold chain" discipline is evolving 
• The top industry trends & challenges that will define the year ahead
• The key innovators driving the industry forward
• How industry leaders are building more resilient, agile and transparent supply chains